Patent classifications
C07D515/22
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators
- Jeremy J. Clemens ,
- Alexander Russell Abela ,
- Corey Don Anderson ,
- Brett B. Busch ,
- Weichao George Chen ,
- Thomas Cleveland ,
- Timothy Richard Coon ,
- Bryan Frieman ,
- Senait G. Ghirmai ,
- Peter Grootenhuis ,
- Anton V. Gulevich ,
- Sara Sabina Hadida Ruah ,
- Clara Kuang-Ju Hsia ,
- Ping Kang ,
- Haripada Khatuya ,
- Jason McCartney ,
- Mark Thomas Miller ,
- Prasuna Paraselli ,
- Fabrice Pierre ,
- Sara E. Swift ,
- Andreas Termin ,
- Johnny Uy ,
- Carl V. Vogel ,
- Jinglan Zhou
Compounds of Formula (I):
##STR00001##
pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
MCL-1 INHIBITORS AND METHODS OF USE THEREOF
Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1.sup.4,7.0.sup.11,15.0.sup.16,21.0.sup.20,24.0.sup.30,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I)
##STR00001##
and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1.sup.4,7.0.sup.11,15.0.sup.16,21.0.sup.20,24.0.sup.30,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
MCL-1 INHIBITORS AND METHODS OF USE THEREOF
Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1.sup.4,7.0.sup.11,15.0.sup.16,21.0.sup.20,24.0.sup.30,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I)
##STR00001##
and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1.sup.4,7.0.sup.11,15.0.sup.16,21.0.sup.20,24.0.sup.30,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
ANTITUMORAL COMPOUNDS
A compound of general formula I and pharmaceutical compositions, kits, methods of making, and methods for treating cancer using the same.
##STR00001##
ANTITUMORAL COMPOUNDS
A compound of general formula I and pharmaceutical compositions, kits, methods of making, and methods for treating cancer using the same.
##STR00001##
A LYOPHILIZED PHARMACEUTICAL COMPOSITION
The present invention relates to form B of lurbinectedin of the formula:
##STR00001##
A LYOPHILIZED PHARMACEUTICAL COMPOSITION
The present invention relates to form B of lurbinectedin of the formula:
##STR00001##
CRYSTALLIZED FORM OF LURBINECTEDIN AND METHOD OF MAKING THE SAME
The present invention relates to form B of lurbinectedin of the formula:
##STR00001##
CRYSTALLIZED FORM OF LURBINECTEDIN AND METHOD OF MAKING THE SAME
The present invention relates to form B of lurbinectedin of the formula:
##STR00001##
SYNTHESIS OF DISORAZOLES AND ANALOGS THEREOF AS POTENT ANTICANCER AGENTS
In one aspect, the present disclosure provides disorazole analogs of the formula: Formula (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.
##STR00001##